Zacks Research Brokers Reduce Earnings Estimates for JNJ

Johnson & Johnson (NYSE:JNJ) – Equities researchers at Zacks Research dropped their Q2 2025 earnings per share (EPS) estimates for shares of Johnson & Johnson in a research report issued to clients and investors on Tuesday, January 7th. Zacks Research analyst K. Shah now forecasts that the company will post earnings of $2.67 per share for the quarter, down from their previous forecast of $2.68. The consensus estimate for Johnson & Johnson’s current full-year earnings is $9.94 per share. Zacks Research also issued estimates for Johnson & Johnson’s Q3 2025 earnings at $2.68 EPS.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, beating analysts’ consensus estimates of $2.21 by $0.21. The business had revenue of $22.47 billion during the quarter, compared to the consensus estimate of $22.17 billion. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. Johnson & Johnson’s revenue for the quarter was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $2.66 earnings per share.

Other equities research analysts have also recently issued reports about the company. Royal Bank of Canada upped their target price on Johnson & Johnson from $178.00 to $181.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 16th. Morgan Stanley raised their price objective on Johnson & Johnson from $169.00 to $175.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 16th. Citigroup lowered their target price on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a research note on Wednesday, December 11th. Wells Fargo & Company raised their price target on shares of Johnson & Johnson from $163.00 to $166.00 and gave the company an “equal weight” rating in a research note on Wednesday, October 16th. Finally, Bank of America reiterated a “neutral” rating and set a $166.00 price objective on shares of Johnson & Johnson in a research report on Tuesday, December 10th. Seven equities research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus target price of $174.71.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ opened at $142.10 on Thursday. The firm has a 50 day moving average of $150.03 and a 200-day moving average of $156.04. The stock has a market capitalization of $342.12 billion, a PE ratio of 20.56, a PEG ratio of 2.52 and a beta of 0.51. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. Johnson & Johnson has a 12 month low of $141.44 and a 12 month high of $168.85.

Institutional Investors Weigh In On Johnson & Johnson

Several institutional investors and hedge funds have recently made changes to their positions in the business. Legacy Private Trust Co. boosted its stake in Johnson & Johnson by 8.4% during the fourth quarter. Legacy Private Trust Co. now owns 39,173 shares of the company’s stock worth $5,665,000 after acquiring an additional 3,047 shares in the last quarter. Douglas Lane & Associates LLC boosted its holdings in Johnson & Johnson by 1.1% in the fourth quarter. Douglas Lane & Associates LLC now owns 599,386 shares of the company’s stock worth $86,683,000 after acquiring an additional 6,526 shares in the last quarter. InvesTrust bought a new stake in shares of Johnson & Johnson during the fourth quarter valued at approximately $6,355,000. Fulton Bank N.A. raised its position in shares of Johnson & Johnson by 7.8% during the fourth quarter. Fulton Bank N.A. now owns 47,550 shares of the company’s stock worth $6,877,000 after purchasing an additional 3,427 shares during the period. Finally, Innova Wealth Partners acquired a new stake in Johnson & Johnson in the 4th quarter valued at $416,000. Institutional investors own 69.55% of the company’s stock.

Insider Buying and Selling at Johnson & Johnson

In other Johnson & Johnson news, Director Mark A. Weinberger purchased 1,000 shares of the firm’s stock in a transaction on Thursday, December 12th. The stock was purchased at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the acquisition, the director now owns 1,000 shares in the company, valued at approximately $147,220. The trade was a ∞ increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be issued a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 3.49%. The ex-dividend date of this dividend is Tuesday, February 18th. Johnson & Johnson’s payout ratio is presently 71.78%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.